Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir alafenamide versus entecavir for chronic hepatitis B with fatty liver
ChiCTR2000041005Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir alafenamide and entecavir in Chronic Hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Hepatitis B surface antigen quantity, HBV DNA quantity and 5 more. Started Jan 2021; status: recruiting.
02
Drugs
tenofovir alafenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2000041005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041005.